A detailed history of Virtus ETF Advisers LLC transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Virtus ETF Advisers LLC holds 2,369 shares of IDYA stock, worth $65,787. This represents 0.04% of its overall portfolio holdings.

Number of Shares
2,369
Previous 2,325 1.89%
Holding current value
$65,787
Previous $81,000 7.41%
% of portfolio
0.04%
Previous 0.04%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$30.37 - $43.05 $1,336 - $1,894
44 Added 1.89%
2,369 $75,000
Q2 2024

Aug 14, 2024

SELL
$34.37 - $43.46 $7,217 - $9,126
-210 Reduced 8.28%
2,325 $81,000
Q1 2024

May 15, 2024

SELL
$34.2 - $47.13 $5,814 - $8,012
-170 Reduced 6.28%
2,535 $111,000
Q4 2023

Feb 15, 2024

SELL
$24.59 - $35.83 $31,278 - $45,575
-1,272 Reduced 31.98%
2,705 $96,000
Q3 2023

Nov 07, 2023

SELL
$21.07 - $29.77 $8,449 - $11,937
-401 Reduced 9.16%
3,977 $107,000
Q2 2023

Aug 14, 2023

SELL
$13.33 - $25.53 $21,248 - $40,694
-1,594 Reduced 26.69%
4,378 $102,000
Q1 2023

May 15, 2023

SELL
$13.49 - $18.72 $30,851 - $42,812
-2,287 Reduced 27.69%
5,972 $81,000
Q4 2022

Feb 14, 2023

SELL
$14.47 - $18.17 $12,979 - $16,298
-897 Reduced 9.8%
8,259 $150,000
Q3 2022

Nov 14, 2022

BUY
$9.24 - $15.79 $628 - $1,073
68 Added 0.75%
9,156 $137,000
Q2 2022

Aug 12, 2022

BUY
$8.28 - $13.88 $15,698 - $26,316
1,896 Added 26.36%
9,088 $125,000
Q1 2022

May 16, 2022

SELL
$11.18 - $24.02 $4,807 - $10,328
-430 Reduced 5.64%
7,192 $80,000
Q4 2021

Feb 14, 2022

SELL
$20.95 - $26.88 $43,010 - $55,184
-2,053 Reduced 21.22%
7,622 $180,000
Q3 2021

Nov 15, 2021

SELL
$17.26 - $27.08 $8,664 - $13,594
-502 Reduced 4.93%
9,675 $247,000
Q2 2021

Aug 10, 2021

BUY
$17.76 - $24.83 $180,743 - $252,694
10,177 New
10,177 $214,000

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.33B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track Virtus ETF Advisers LLC Portfolio

Follow Virtus ETF Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus ETF Advisers LLC with notifications on news.